Eli Lilly doubles down on Oblique partnership for antibody generation
The two companies have expanded their agreement first inked in 2023, with a second ‘high-value target’ now in the crosshairs.
The two companies have expanded their agreement first inked in 2023, with a second ‘high-value target’ now in the crosshairs.
What's Your Reaction?
